electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 7.16 USD -1.04% Market Closed
Market Cap: 46.9m USD

electroCore, Inc.
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Non-Reccuring Items
-$480m
CAGR 3-Years
-13%
CAGR 5-Years
0%
CAGR 10-Years
-36%
Boston Scientific Corp
NYSE:BSX
Non-Reccuring Items
-$402m
CAGR 3-Years
24%
CAGR 5-Years
-6%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Non-Reccuring Items
-$1.4B
CAGR 3-Years
-14%
CAGR 5-Years
-15%
CAGR 10-Years
-3%
Abbott Laboratories
NYSE:ABT
Non-Reccuring Items
-$350m
CAGR 3-Years
-29%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

electroCore, Inc.
Glance View

Market Cap
47.6m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
20.73 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

Back to Top